Anemia Clinical Trial
Official title:
Impact of Full Correction of Post-transplant Anemia on the Cardiovascular System and Quality of Life in Renal Transplant Recipients Receiving Erythropoietin Stimulating Agents: a Prospective Randomized Controlled Trial.
Background:
Post-transplant anemia (PTA) might be associated cardiovascular morbidity and even increased
mortality. Objectives:
We aimed to assess the impact of full correction of chronic PTA on cardiovascular system and
quality of life in renal transplant recipients with stable graft function using
erythropoietin stimulating agents.
Patient and methods: We enrolled 247 kidney recipients with stable graft function to be
assessed for anemia. Eligible patients were randomized to achieve target hemoglobin between
11 to 12 g/dl (group 1, n=183), or 13 to 15 g/dl (in group 2, n=64) using ESA. Monthly
clinical and laboratory evaluation of kidney graft function was carried out. Moreover,
quality of life (QOL) and echocardiography were assessed at the start and at 12 months.
Two hundred and eighty anemic renal transplant recipients with stable graft function- who are
followed up in Hamed Al-Essa organ transplant centre - will be assessed for the possible
causes of their anemia. Anemia will be defined as Revised European Best Practice guidelines
for anemia in renal tx, a Hb level of <11 g/dl should trigger treatment with ESA.
Drugs:
After patients' assessment for possible causes of anemia, each patient will be managed
according to the specific cause of anemia i.e. iron, folic, and vitamin b12 deficiencies will
be corrected. If anemia will be improved, we will consider such group of patients as
corrected group, but if we failed to find specific cause of anemia we will consider them for
ESA. Iron supplementation is permitted in order to maintain serum ferritin in the range
100-800 ng/ml or transferring saturation (TSAT) in the range 20-50%. Medications known to
affect Hb concentration-e.g. angiotensin converting enzyme inhibitors (ACEI) & angiotensin
receptor blockers (ARBS) - will be maintained at a stable dose if already prescribed at the
start of the study.
Patients who fulfilled the following criteria will be included in the study:
Adult renal transplant patients (≥18 years). Informed consent. Stable maintenance
subcutaneous darbepoetin alfa therapy with constant dose interval during the last 2 months.
Haemoglobin (Hb) ≥10mg/dL (Hct 32%). Transferrin saturation (TSAT) ≥20% (during the screening
phase) Serum ferritin ≥100 ng/mL
We will exclude patients with the following criteria:
Acute or chronic bleeding, or erythrocyte transfusion, within the preceding 8 weeks.
Change in Hb level ≥ 2 g/dL during screening phase. Hemolytic anemia. Recent infection or
rejection Diastolic blood pressure >100mmHg or discontinuation of ESA due to hypertension in
the 6 months prior to study.
Vitamin B12 or folic acid deficiency. Uncontrolled or secondary hyperparathyroidism. Acute or
chronic systemic inflammatory disease and/or C-reactive protein (CRP) >30 mg/L.
Hemodialysis due to the failure of a kidney transplant. Malignancy. Eligible patients will be
randomized to either target hemoglobin between 11 to 12 gram/dl (group 1), or target
hemoglobin between 13 to 15 gram/dl (group 2). The target HB will be achieved using either
darbepoetin α once weekly or once every 2 weeks or equivalent dosage of monthly CERA and the
dosage will be adjusted during the titration and evaluation phase according to table 1.
The maintenance dosage of each agent will be modified according to the response (hemoglobin
changes). In case of any emergencies, the patient will be managed in Hamed Al-Issa organ
transplant Centre 24 hours per day. Mobile of the 1st on-call doctor is ( ); Tel of OTC, ward
1(24826490 &24840300 ext. 4100)".
Randomization:
Patients will be classified according to the maintenance dose of ESA, then they will be
sub-grouped into males and females. All patients in each subgroup will be arranged
alphabetical using Excel program, and a number will be given to each patient. Patients with
odd numbers will serve as group1 while those with even numbers will serve as group 2.
Patients' files will be marked with sticker according to the corresponding group to
facilitate collection of data.
Methods:
Each patient will be evaluated:
Clinically by history taking and thorough medical examination every month in the outpatient
clinic.
By Laboratory investigations which will include:
CBC*, HB electrophoresis, Iron-Ferritin- Transferrin saturation, PT(INR) B12, folic acid
levels PTH, CR protein, ESR
- Serum cr., Cr cl, LFT, ca/ph, FBS
- Urinary protein (gm / 24h )
- Drug levels Virology profile (CMV, EBV, Parvovirus ) The radiological investigation
using abdominal US, echocardiography and carotid Doppler ultrasound.
Quality of life will be assessed in each patient using 25 and 36 questionnaires at the start
of enrollment and by the end of 12 months of achieving the target hemoglobin.
NB.1- * indicates that these test will be every month, while other tests will be only at the
initial assessment.
2-Blood samples will be sent to the corresponding laboratory without storage and results will
be collected according to the laboratory schedule.
3-As the drugs utilized in such study is available for all patients (Kuwaiti and
non-Kuwaiti), we will proceed smoothly. However, some of the laboratory tests will need
patients own financial support (especially the non-Kuwaiti).
Data analysis:
Descriptive parameters (mean, standard deviation, median, range, and the number of
observations) will be presented for continuous observations.
Frequencies (absolute and percentage) are to be shown for qualitative variables (e.g., sex,
ethnicity, Hb values within target ranges and occurrence of adverse events).
The safety population will compromise all patients who received at least one dose of study
medication. All patients in the safety population who provided at least one Hb value during
C.E.R.A. therapy will be included in the intention-to-treat (ITT) population
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Active, not recruiting |
NCT02101944 -
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |